Company / Interest Expense
RIGEL PHARMACEUTICALS INC Interest Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$7.9M
FY2024
5-year range
$3.7M / $7.9M
FY2020-FY2024
Trend
+15.2%
vs FY2023
Sector context
#31 of 44
Health Care
What the data says
At $8M, RIGEL PHARMACEUTICALS INC's interest expense ranks #14 of 44 in the Health Care sector. Increased from $4M to $8M over the past 2 years.
Based on SEC 10-K filings.
$8M in FY2024 with a 5-year CAGR of +88.2%.
Increased from $4M to $8M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +17.7%
- 5-Year CAGR
- +88.2%
- 10-Year CAGR
- -
Sector benchmark
#14 of 44 in Health CareTop 30% of 44This company $7.9M Sector average $291.0M
▼
-97.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +88.2%, indicating consistent growth.
- In FY2024, interest expense increased 15.2% year-over-year.
- Ranks #31 out of 44 companies in the Health Care sector.
- Lowest interest expense in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $7.9M | +15.2% |
| FY2023 | $6.9M | +85.4% |
| FY2022 | $3.7M | -23.7% |
| FY2021 | $4.9M | +259.2% |
| FY2020 | $1.4M | +303.9% |
| FY2019 | $335.0K | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026